Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-Blind, Randomized, Parallel-group, Study Evaluating PK, Efficacy, Safety, and Immunogenicity in Patients With Plaque Psoriasis Receiving Humira® or AVT02 Followed by a Safety Extension Phase of AVT02

NCT04453137 is registered in ClinicalTrials.gov with Alvotech Swiss AG as lead sponsor.

NCT NCT04453137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04453137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-Blind, Randomized, Parallel-group, Study Evaluating PK, Efficacy, Safety, and Immunogenicity in Patients With Plaque Psoriasis Receiving Humira® or AVT02 Followed by a Safety Extension Phase of AVT02
Lead sponsor
Alvotech Swiss AG
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2020
Completion date
November 16, 2021
Enrollment
567 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis